The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The value of pulse cyclophosphamide in ANCA‐associated vasculitis: meta‐analysis and critical review
Abstract
BACKGROUND: The study aimed at studying efficacy and adverse effects of pulse cyclophosphamide (pCyc) treatment and to compare it to continuous cyclophosphamide (cCyc) for induction of remission in ANCA-associated vasculitides from data in the published literature. METHODS: A Medline search identified 14 studies, containing more than five patients. From the 11 non-randomized studies, data on outcome following pCyc treatment were extracted. Results were given as fraction of the number of evaluable patients. A meta-analysis was performed on the three prospective, randomized controlled trials to compare outcomes concerning remission, relapses, infection, leucopenia, death and renal failure in patients treated with pCyc as opposed to cCyc. RESULTS: The 11 non-randomized studies comprised 202 patients receiving pCyc. Cyc pulses of 375-1000 mg/sqm/pulse were applied at weekly to monthly intervals with different concomitant prednisolone regimens and variable adjunctive therapy. Complete remission was achieved in 112/191, partial remission in 23/191 evaluable patients. Relapses occurred in 68/135 patients, 40/115 patients were non-responders. Leucopenia, infections, haemorrhagic cystitis, and deaths were rare. The meta-analysis, comprising 143 patients, showed that pCyc compared with cCyc treatment was significantly less likely to fail to induce remission (OR 0.29; 95% CI 0.12-0.73) and had a significantly lower risk of infection (OR 0.45; 95% CI 0.23-0.89) and leucopenia (OR 0.36; 95% CI 0.17-0.78). Relapses occurred slightly, although not statistically significantly, more often under pCyc treatment (OR 1.79; 95% CI 0.85-3.75). There were no differences in end-stage renal failure or deaths between the two regimens. CONCLUSIONS: The currently available, rather sparse data show that pCyc is less toxic than cCyc therapy and is an at least equally potent inductor of remission, but possibly at the expense of a higher relapse rate. The existing data do not give sufficient information on outcomes as time to remission and relapse, irreversible damage or quality of life without which a treatment regimen cannot satisfactorily be evaluated today. A large prospective randomized controlled trial is needed to address these issues and their relative importance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
FAUCI, A. S., HAYNES, B. F., KATZ, P., & WOLFF, S. M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-76 · Cited by 2,001
Guillevin, L., Cordier, J., Lhote, F., Cohen, P., Jarrousse, B., Royer, I., Lesavre, P., Jacquot, C., Bindi, P., Bielefeld, P., et al. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780401213 · Cited by 509
Falk, R. J., Hogan, S., Carey, T. S., Jennette, J. C., & The Glomerular Disease Collaborative Network (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-9-656 · Cited by 391
Westman, K. W., Bygren, P. G., Olsson, H., Ranstam, J., & Wieslander, J. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v95842 · Cited by 318
Adu, D. (1997) · QJM · doi:10.1093/qjmed/90.6.401 · Cited by 228
Self-citationTreatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide
Hoffman, G. S., Leavitt, R. Y., Fleisher, T. A., Minor, J. R., & Fauci, A. S. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90367-m · Cited by 201
Reinhold‐Keller, E., Kekow, J., Schnabel, A., Schmitt, W. H., Heller, M., Beigel, A., Duncker, G., & Gross, W. L. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370622 · Cited by 166
Martín-Suárez, I. J., D’Cruz, D. P., Mansoor, M., Fernandes, A. P., Khamashta, M. A., & Hughes, G. R. V. (1997) · Annals of the Rheumatic Diseases · doi:10.1136/ard.56.8.481 · Cited by 127
Evidence‐based treatment of systemic vasculitis
Jayne, D. R. W. (2000) · Rheumatology · doi:10.1093/rheumatology/39.6.585 · Cited by 96
Cited by
Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020286 · Cited by 1,348
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Yates, M., Watts, R. A., Bajema, I. M., Cid, M. C., Crestani, B., Hauser, T., Hellmich, B., Holle, J. U., Laudien, M., Little, M. A., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209133 · Cited by 1,194
EULAR recommendations for the management of primary small and medium vessel vasculitis
Mukhtyar, C., Guillevin, L., Cid, M. C., Dasgupta, B., de Groot, K., Gross, W., Hauser, T., Hellmich, B., Jayne, D., Kallenberg, C. G. M., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088096 · Cited by 990
de Groot, K., Harper, L., Jayne, D. R. W., Flores Suarez, L. F., Gregorini, G., Gross, W. L., Luqmani, R., Pusey, C. D., Rasmussen, N., Sinico, R. A., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-10-200905190-00004 · Cited by 957
Self-citationAzathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis
Dhawan, R. (2009) · Yearbook of Medicine · doi:10.1016/s0084-3873(09)79350-2 · Cited by 674
Metadata
- Authors
- Groot, K. D., Adu, D., & Savage, C. O. S.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-10-01
- Volume
- 16
- Issue
- 10
- Pages
- 2018-2027
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2140547944
- Cited by
- 335
- References
- 11
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The value of pulse cyclophosphamide in ANCA‐associated vasculitis: meta‐analysis and critical review. https://app.cochat.ai/papers/10.1093/ndt/16.10.2018
- The paper
- Groot, K. D., Adu, D., & Savage, C. O. S. (2001). The value of pulse cyclophosphamide in ANCA‐associated vasculitis: meta‐analysis and critical review. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/16.10.2018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.